Table 1.
Baseline demographics, clinical characteristics, and medication adherence of the study participants.
| TAC-ER (n = 9) | TAC-IR (n = 16) | p value | |
|---|---|---|---|
| Age, mean (SD) | 52 (12.5) | 55.6 (12.2) | 0.49 |
| Ethnicity, n (%) | |||
| Caucasian | 6 (67%) | 10 (62%) | 0.86 |
| African American | 2 (22%) | 4 (25%) | |
| Hispanic | 1 (11%) | 1 (6%) | |
| Asian | 0 (0%) | 1 (6%) | |
| Gender, n (%) | |||
| Male | 2 (22%) | 10 (62%) | 0.053 |
| Female | 7 (78%) | 6 (38%) | |
| Level of education, n (%) | |||
| High school/GED | 5 (56%) | 6 (38%) | 0.21 |
| Some college | 0 (0%) | 6 (38%) | |
| Bachelors | 3 (33%) | 3 (19%) | |
| Masters or above | 1 (11%) | 1 (6%) | |
| Marital status, n (%) | |||
| Single | 4 (44%) | 3 (19%) | 0.31 |
| Married | 5 (56%) | 9 (56%) | |
| Divorced | 0 (0%) | 3 (19%) | |
| Widowed | 0 (0%) | 1 (6%) | |
| Time from LT to enrollment, median years (IQR) | 1.4 (0.8, 2.8) | 1.0 (0.6, 3.0) | 0.82 |
| Time from LT to enrollment <1 yr, n (%) | 4 (44%) | 7 (47%) | 0.92 |
| Baseline tacrolimus trough level, mean ng/mL (SD) | 7.7 (2.0) | 6.0 (2.2) | 0.096 |
| Baseline tacrolimus dose, mean mg/day (SD) | 7.2 (1.8) | 4.9 (2.6) | 0.022 |
| Mean trough level ng/mL, week 1-month 9 (IQR) | 6.5 (9.4) | 6.65 (7.5) | 0.28 |
| Mean trough level ng/mL, week 1-month 9, mean (SD) | 7.6 (2.1) | 6.3 (2.0) | 0.14 |
| Acute rejection, n (%) | 1 (17%) | 1 (11%) | 0.76 |
| Any nonadherence at baseline | 3 (33%) | 10 (62%) | 0.16 |
| BAASIS adherence at baseline | |||
| Never taken as prescribed | 0 (0%) | 1 (6%) | 0.33 |
| Sometimes taken as prescribed | 3 (33%) | 9 (56%) | |
| Always taken as prescribed | 6 (67%) | 6 (38%) | |
| BAASIS adherence at 4 weeks | |||
| Never taken as prescribed | 0 (0%) | 0 (0%) | 0.22 |
| Sometimes taken as prescribed | 2 (29%) | 8 (57%) | |
| Always taken as prescribed | 5 (71%) | 6 (43%) | |
| BAASIS adherence at 3 months | |||
| Never taken as prescribed | 0 (0%) | 1 (8%) | 0.053 |
| Sometimes taken as prescribed | 2 (22%) | 8 (67%) | |
| Always taken as prescribed | 7 (78%) | 3 (25%) | |
| BAASIS adherence at 6 months | |||
| Never taken as prescribed | 0 (0%) | 0 (0%) | 0.26 |
| Sometimes taken as prescribed | 3 (38%) | 7 (64%) | |
| Always taken as prescribed | 5 (62%) | 4 (36%) | |
| BAASIS adherence at 9 months | |||
| Never taken as prescribed | 0 (0%) | 0 (0%) | 0.14 |
| Sometimes taken as prescribed | 1 (14%) | 7 (47%) | |
| Always taken as prescribed | 6 (86%) | 8 (53%) | |
| Full-adherence throughout the study | 2 (22%) | 1 (6%) | 0.24 |
| At least one-time full adherence | 9 (100%) | 10 (62%) | 0.035 |